This profile was last updated on .
Is this you? Claim your profile.
Institute of Cancer Research
Sir Richard Doll Building 15 Cotswold Road
The Institute of Cancer Research is Europe's leading cancer research centre with expert scientists working on cutting edge research. It was founded in 1909 to carry out research into the causes of cancer and to develop new strategies for cancer prevention...
Find other employees at this company (7,700)
(184 Total References)
Mitch Dowsett, PhD, ...
Mitch Dowsett, PhD, FMedSci
Mitch Dowsett, PhD, FMedSci
Mitch Dowsett, PhD, FMedSci, is a clinical scientist who has over 540 papers listed on PubMed.
He is Head of the Academic Department of Biochemistry and of the Centre for Molecular Pathology at the Royal Marsden Hospital.
He is Professor of Biochemical Endocrinology at the Institute of Cancer Research and of Translational Research in the Breakthrough Breast Cancer Centre in London, UK.
major research interests involve hormonal aspects of breast cancer and the application of biomarkers in clinical trials.
was a major player in the development of aromatase inhibitors, now the most widely used endocrine agent for postmenopausal breast cancer patients and chairs the Aromatase Inhibitor Overview Group
that co-ordinates the collaborative assessment of the merged data from the international trials.
He is a member of the ASCO/CAP Steering Committees for guidelines on both HER2 and steroid receptors and he co-chairs the International Working Group on Ki67 in Breast Cancer.
He was the founding chairman of the National Cancer Research Institute's Biomarker and Imaging Clinical Study Group.
is particularly interested in the evaluation of new and established agents in presurgical studies of breast cancer including being co-PI of the 4,450 patient POETIC trial, the largest study conducted to date.
He sits on the Executive and/or Steering Committees of many international trials and served for 7 years on the Executive Committee of the Breast International Group (BIG).
has received the William L. McGuire Award and the Brinker Award for Scientific Distinction and has given multiple named lectures.
Prof. Mitch ...
Prof. Mitch Dowsett
Head of the Academic Department of Biochemistry and Head of Breast Cancer Translational Research, Royal Marsden Hospital
and Institute of Cancer Research
, London, England
Pharmacy news - Daily Online Canadian Pharmacy News Articles
The first study was led by Mitch Dowsett, of The Royal Marsden Hospital and The Institute of Cancer Research, and assessed over 30,000 early breast cancer patients who were postmenopausal.
The women took an AI or tamoxifen, the standard treatment drug, for five years.
The AI group saw a 15 percent drop in risk of death and 30 percent reduction in risk of cancer.
Dowsett said, "Our global collaboration has revealed that the risk of postmenopausal women with the most common form of breast cancer dying of their disease is reduced by 40 percent by taking five years of an AI - a significantly greater protection than that offered by tamoxifen."
Radius Health also announced ...
Radius Health also announced today that it has formed an Oncology Clinical Advisory Board (OCAB) comprised initially of two renowned leaders in the field of oncology: Professor Mitch Dowsett, FMedSci, PhD, and Professor George W. Sledge Jr.
In addition, we are honored to have the esteemed counsel of two of the leading authorities in the field of breast cancer research, Professor Dowsett and Professor Sledge, join our newly formed OCAB," said Radius Health CEO, Robert E. Ward.
Radius is pleased to announce the formation of the OCAB with its first two members, both of whom are world renowned scientific and clinical authorities in the field of oncology: Professor Mitch Dowsett, and Professor George Sledge.
Professor Mitch Dowsett, FMedSci, PhD, is Head of the Academic Department of Biochemistry and Head of the Centre for Molecular Pathology at the Royal Marsden Hospital in London, UK.
He is also Professor of Biochemical Endocrinology at the Institute of Cancer Research, Professor of Translational Research in the Breakthrough Breast Cancer Centre, Team Leader for Breast Cancer Research for the Biomedical Research Centre for Cancer and Leader of the Endocrinology Team at the Breakthrough Breast Cancer Centre.
main scientific interests have been related to the endocrine basis of the majority of breast cancers, and his
studies to understand the mechanisms of response and resistance to estrogen deprivation in the treatment of breast cancer.
studies led to the development of aromatase inhibitors.
"But aromatase inhibitor treatment is not ...
"But aromatase inhibitor treatment is not free of side-effects and it's important to ensure that women" who suffer them are "supported", said the study's lead author, Mitch Dowsett of The Institute of Cancer Research in London.